A5024494114- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiovascular and exercise physiology
- Blood Pressure and Hypertension Studies
- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research
- Inflammasome and immune disorders
- Diabetes Treatment and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Fibrosis and Remodeling
- Venous Thromboembolism Diagnosis and Management
- Adipokines, Inflammation, and Metabolic Diseases
- Lipoproteins and Cardiovascular Health
- Cardiovascular Health and Risk Factors
- Cardiovascular Disease and Adiposity
- Chronic Kidney Disease and Diabetes
- Potassium and Related Disorders
- Pharmaceutical Practices and Patient Outcomes
- Iron Metabolism and Disorders
- GDF15 and Related Biomarkers
- Health Systems, Economic Evaluations, Quality of Life
- Medication Adherence and Compliance
- Atherosclerosis and Cardiovascular Diseases
- Cardiovascular Syncope and Autonomic Disorders
- Pulmonary Hypertension Research and Treatments
Brigham and Women's Hospital
2015-2025
Mercy University Hospital
2024
Harvard University
2020-2023
Virginia Commonwealth University
2016-2022
Baylor College of Medicine
2021
E Ink (South Korea)
2016-2020
MedStar Washington Hospital Center
2020
Jackson Memorial Hospital
2020
University of Illinois Chicago
2017-2018
Istituto Neurologico Mediterraneo
2016-2017
Background ST-segment-elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin-1 blockade anakinra significantly reduced the area under curve for hsCRP (high sensitivity C-reactive protein) levels during first 14 days in patients (VCUART3 [Virginia Commonwealth University Anakinra Remodeling Trial 3]). Methods Results conducted a randomized, placebo-controlled, double-blind, clinical trial 99 which were...
Background An enhanced inflammatory response predicts worse outcomes in heart failure (HF). We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the and improve peak aerobic exercise capacity patients with recently decompensated systolic HF. Methods Results randomly assigned 60 reduced left ventricular ejection fraction (<50%) elevated C-reactive protein levels (>2 mg/L), within 14 days hospital discharge, to daily subcutaneous...
Background Enhanced inflammation may lead to exercise intolerance in heart failure with preserved ejection fraction. The aim of the current study was determine whether IL (interleukin)-1 blockade anakinra improved cardiorespiratory fitness Methods and Results Thirty-one patients fraction CRP (C-reactive protein) >2 mg/L were randomized (100 mg subcutaneously daily, N=21) or placebo (N=10) for 12 weeks. We measured peak oxygen consumption (Vo2), ventilatory efficiency (VE/Vco2 slope),...
Abstract Heart failure (HF) causes substantial morbidity and mortality but its pathobiology is incompletely understood. The proteome a promising intermediate phenotype for discovery of novel mechanisms. We measured 4877 plasma proteins in 13,900 HF-free individuals across three analysis sets with diverse age, geography, HF ascertainment to identify circulating protein networks associated development. Parallel analyses Atherosclerosis Risk Communities study participants mid-life late-life...
Background: Heart failure is an inflammatory disease. Patients with acute decompensated heart (ADHF) exhibit significant activity on admission. We hypothesized that Interleukin-1 blockade, anakinra (Kineret, Swedish Orphan Biovitrum), would quench the response in patients ADHF. Methods: randomized 30 ADHF, reduced left ventricular ejection fraction (<40%), and elevated C reactive protein (CRP) levels (≥5 mg/L) to either 100 mg twice daily for 3 days followed by once 11 or matching placebo, a...
OBJECTIVE We sought to determine the effect of intensive blood pressure (BP) control on cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional risk factors for disease (CVD). RESEARCH DESIGN AND METHODS This study was a post hoc, multivariate, subgroup analysis ACCORD-BP (Action Control Cardiovascular Risk Diabetes Blood Pressure) participants. Participants were eligible if they standard glucose arm also had CVD required SPRINT (Systolic Pressure...
Abstract Aims Interleukin-6 (IL-6) and interleukin-18 (IL-18), important cytokines implicated in atherosclerosis inflammaging, were assessed for associations with global cardiovascular disease (CVD), atrial fibrillation (AF), death older adults. Methods results Participants from Atherosclerosis Risk Communities study Visit 5 (mean age 75.4 ± 5.1 years) IL-6 IL-18 measurements included (n = 5672). Cox regression models used to assess of coronary heart (CHD), ischaemic stroke, failure (HF)...
In the COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) coronary artery disease trials, low-dose colchicine decreased risk of major adverse cardiovascular events (MACEs) by 23% to 31% beyond statin therapy with a strong safety profile. The number MACE potentially preventable widespread use in United States remains uncertain. objective this study was estimate current potential impact on outcomes. We first calculated new users before after publication at an...
Heart failure with preserved ejection fraction (HFpEF) is associated obesity and, indirectly, unhealthy diet. The role of dietary components in HFpEF is, however, largely unknown. In this study, the authors showed that obese patients, consumption unsaturated fatty acids (UFA), was better cardiorespiratory fitness, and UFA correlated diastolic function greater fat-free mass. Similarly, mice fed a high-fat diet rich low sugars had myocardial reduced weight gain. Randomized clinical trials...
Heart failure with preserved ejection fraction ( HFpEF ) now accounts for the majority of confirmed HF cases in United States. However, there are no highly effective evidence‐based treatments currently available these patients. Inflammation correlates positively adverse outcomes Interleukin IL )‐1, a prototypical inflammatory cytokine, has been implicated as driver diastolic dysfunction preclinical animal models and pilot clinical trial. The Diastolic Failure Anakinra Response Trial 2 (D‐...
Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that presents clinicians diagnostic challenge. The use of natriuretic peptides to exclude diagnosis HFpEF has been proposed. We sought compare patients N‐terminal pro‐brain peptide (NT‐proBNP) level above and below the proposed cut‐off. Methods Stable ( n = 30) left ventricular (LV) ≥ 50% were eligible if they had HF according European Society Cardiology criteria. Characteristics NT‐proBNP...
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease progression and mortality in patients with chronic (CKD), regardless of diabetes status. However, the prescribing patterns these novel therapeutics CKD population real-world settings remain largely unknown.
Whether time-in-target range (TTR) for systolic blood pressure (SBP) associates with adverse kidney and cardiovascular events remains incompletely understood.
Importance The prevalence of absolute and functional iron deficiency among adults in the US is unknown. Objective To estimate supplement use across age, sex, comorbidity categories. Design, Setting, Participants This cross-sectional study analyzed data from National Health Nutritional Examination Survey (NHANES) 2017 to 2020 prepandemic cycle. included noninstitutionalized, civilian women men aged 18 years or older who had available serum ferritin, iron, unsaturated binding capacity...